Crispr Therapeutics shares tumble after significant earnings miss
SPS Commerce Inc. (NASDAQ:SPSC) stock has reached a new 52-week low, closing at 115.5 USD, significantly below its 52-week high of 218.61 USD. According to InvestingPro data, the company maintains strong fundamentals with a 67.7% gross profit margin and healthy revenue growth of 19.5% over the last twelve months. This marks a significant point for the company, as the stock has experienced a notable decline over the past year. The 1-year change for SPS Commerce Inc. stands at -33.21%, reflecting the challenges the company has faced in maintaining its market position. Eight analysts have recently revised their earnings expectations downward, though the company maintains a solid financial health score. This downward trend highlights the pressures within the industry and the potential need for strategic adjustments to regain investor confidence and stabilize stock performance. For deeper insights into SPSC’s valuation and growth prospects, including 10 additional key ProTips, visit InvestingPro.
In other recent news, SPS Commerce reported stronger-than-expected earnings for the second quarter of 2025. The company achieved earnings per share of $1.00, exceeding the forecast of $0.91, and revenue reached $187.4 million, slightly above the expected $185.82 million. Despite these positive results, the company’s revenue was on the lower end of its historical range. Needham responded by lowering its price target for SPS Commerce to $160.00 from $210.00, while maintaining a Buy rating. Loop Capital also made adjustments, downgrading SPS Commerce from Buy to Hold and reducing its price target to $120.00 from $175.00, citing growth concerns. Both firms acknowledged the company’s performance surpassed their expectations and the high end of company guidance. These developments reflect ongoing evaluations by analysts regarding SPS Commerce’s future growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.